$1.11 Billion is the total value of Redmile Group, LLC's 54 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 138.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Buy | ARRAY BIOPHARMA INC | $96,736,000 | +72.5% | 13,125,594 | +10.7% | 8.69% | +42.2% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $66,872,000 | +65.5% | 900,879 | +24.8% | 6.00% | +36.5% |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDadr | $53,203,000 | – | 853,973 | +100.0% | 4.78% | – |
| ENDP | New | ENDO INTL PLC | $50,272,000 | – | 560,443 | +100.0% | 4.51% | – |
| ASPX | New | AUSPEX PHARMACEUTICALS INC | $41,866,000 | – | 417,533 | +100.0% | 3.76% | – |
| BIIB | Buy | BIOGEN INC | $41,258,000 | +181.9% | 97,713 | +126.6% | 3.70% | +132.5% |
| SGEN | Buy | SEATTLE GENETICS INC | $37,212,000 | +17.7% | 1,052,666 | +7.0% | 3.34% | -2.9% |
| ALR | New | ALERE INC | $32,476,000 | – | 664,138 | +100.0% | 2.92% | – |
| INSM | Buy | INSMED INC | $28,742,000 | +83.5% | 1,381,828 | +36.5% | 2.58% | +51.4% |
| AET | New | AETNA INC NEW | $22,582,000 | – | 211,974 | +100.0% | 2.03% | – |
| DVA | New | DAVITA HEALTHCARE PARTNERS I | $21,609,000 | – | 265,858 | +100.0% | 1.94% | – |
| HWAY | Buy | HEALTHWAYS INC | $21,158,000 | -0.4% | 1,074,033 | +0.5% | 1.90% | -17.9% |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $20,651,000 | – | 332,600 | +100.0% | 1.85% | – |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $19,930,000 | +36.6% | 1,415,482 | +32.2% | 1.79% | +12.7% |
| CSLT | Buy | CASTLIGHT HEALTH INCcl b | $18,131,000 | +24.2% | 2,336,498 | +87.3% | 1.63% | +2.5% |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $17,279,000 | – | 100,000 | +100.0% | 1.55% | – |
| WOOF | New | VCA INC | $16,874,000 | – | 307,804 | +100.0% | 1.52% | – |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $15,245,000 | +3102.7% | 547,000 | +1995.8% | 1.37% | +2532.7% |
| TKMR | New | TEKMIRA PHARMACEUTICALS CORP | $12,222,000 | – | 700,000 | +100.0% | 1.10% | – |
| KYTH | New | KYTHERA BIOPHARMACEUTICALS I | $11,287,000 | – | 225,062 | +100.0% | 1.01% | – |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $11,025,000 | +56.0% | 265,205 | +0.4% | 0.99% | +28.6% |
| NVTA | New | INVITAE CORP | $10,946,000 | – | 785,131 | +100.0% | 0.98% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $10,855,000 | – | 119,114 | +100.0% | 0.98% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $9,451,000 | – | 796,900 | +100.0% | 0.85% | – |
| CERS | New | CERUS CORP | $6,871,000 | – | 1,647,727 | +100.0% | 0.62% | – |
| BIOS | New | BIOSCRIP INC | $6,105,000 | – | 1,378,200 | +100.0% | 0.55% | – |
| Buy | ARRAY BIOPHARMA INCnote 3.000% 6/0 | $5,022,000 | +168.7% | 4,000,000 | +100.0% | 0.45% | +122.2% | |
| OTIC | New | OTONOMY INC | $2,792,000 | – | 78,972 | +100.0% | 0.25% | – |
| IHF | Buy | ISHARESus hlthcr pr etf | $1,144,000 | +286.5% | 8,599 | +244.0% | 0.10% | +221.9% |
| QQQ | Buy | POWERSHARES QQQ TRUSTunit ser 1 | $454,000 | +27.9% | 4,300 | +25.2% | 0.04% | +5.1% |
| CCXI | New | CHEMOCENTRYX INC | $132,000 | – | 17,500 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.